These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 25556458)
1. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country. Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine pattern of usage, rate of febrile neutropaenia and treatment related death in asian cancer patients in clinical practice. Phua VC; Wong WQ; Tan PL; Bustam AZ; Saad M; Alip A; Wan Ishak WZ Asian Pac J Cancer Prev; 2015; 16(4):1449-53. PubMed ID: 25743814 [TBL] [Abstract][Full Text] [Related]
3. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391 [TBL] [Abstract][Full Text] [Related]
4. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer. Klar N; Rosenzweig M; Diergaarde B; Brufsky A Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763 [TBL] [Abstract][Full Text] [Related]
5. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128 [TBL] [Abstract][Full Text] [Related]
6. Primary and secondary distant metastatic breast cancer: two sides of the same coin. Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572 [TBL] [Abstract][Full Text] [Related]
8. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. Licchetta A; Correale P; Migali C; Remondo C; Francini E; Pascucci A; Magliocca A; Guarnieri A; Savelli V; Piccolomini A; Carli AF; Francini G J Chemother; 2010 Jun; 22(3):201-4. PubMed ID: 20566427 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM; J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968 [TBL] [Abstract][Full Text] [Related]
10. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Kozloff M; Chuang E; Starr A; Gowland PA; Cataruozolo PE; Collier M; Verkh L; Huang X; Kern KA; Miller K Ann Oncol; 2010 Jul; 21(7):1436-1441. PubMed ID: 20032126 [TBL] [Abstract][Full Text] [Related]
11. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996 [TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400 [TBL] [Abstract][Full Text] [Related]
13. Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study. Galli G; Tessari A; Porcu L; Bregni G; Paolini B; Carcangiu ML; Gennaro M; De Santis MC; Lozza L; de Braud F; Di Cosimo S Breast Cancer; 2017 Jul; 24(4):635-641. PubMed ID: 28058615 [TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. Onyenadum A; Gogas H; Markopoulos C; Bafaloukos D; Aravantinos G; Mantzourani M; Koutras A; Tzorakoelefterakis E; Xiros N; Makatsoris T; Fountzilas G; Kalofonos HP J Chemother; 2007 Oct; 19(5):582-9. PubMed ID: 18073159 [TBL] [Abstract][Full Text] [Related]
15. Off-label use of oxaliplatin in patients with metastatic breast cancer. Delpeuch A; Leveque D; Rob L; Bergerat JP Anticancer Res; 2011 May; 31(5):1765-7. PubMed ID: 21617237 [TBL] [Abstract][Full Text] [Related]
16. Radiotherapy in patients with distant metastatic breast cancer. Steinauer K; Gross MW; Huang DJ; Eppenberger-Castori S; Güth U Radiat Oncol; 2014 May; 9():126. PubMed ID: 24885766 [TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168 [TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832 [TBL] [Abstract][Full Text] [Related]
19. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients]. Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471 [TBL] [Abstract][Full Text] [Related]
20. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer. Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]